Anti-Human M-CSF Reference Antibody|抗人M-CSF参考抗体(靶标：人巨噬细胞集落刺激因子)
- 货号：RB9THY515016
- 价格：面议
- 点击：649
产品介绍
产品参数
| 形态 | Liquid |
|---|---|
| 宿主种属 | Humanized |
| 克隆性 | Monoclonal |
| 抗体亚型 | IgG1-kappa |
| 纯度 | >95% as determined by SDS-PAGE. |
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
| 浓度 | 1 mg/ml |
| 内毒素水平 | Please contact with the lab for this information. |
| 应用 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| 种属反应性 | Human |
| 靶标 | CSF1, Macrophage colony-stimulating factor 1, CSF-1, Lanimostim, M-CSF, MCSF |
| 储存缓冲液 | 0.01M PBS, pH 7.4. |
| 稳定性和储存 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. |
| 表达系统 | Mammalian Cells |
| 登录号 | P09603 |
| 背景信息 | Lacnotuzumab, as known as MCS110, is a novel, high-affinity, humanized, anti-CSF-1 monoclonal antibody that prevents CSF-1 from activating the CSF-1R. The drug is being developed by Novartis Europharm Limited. On 15 October 2014, orphan designation (EU/3/14/1350) was granted by the European Commission to Novartis for recombinant human monoclonal antibody of the IgG1 kappa class against human macrophage colony-stimulating factor for the treatment of tenosynovial giant cell tumor, localized and diffuse type. They conducted a phase 1 study to assess the safety and tolerability of administering single ascending doses and repeat doses of lacnotuzumab to healthy volunteers, and to examine the pharmacokinetics (PK), pharmacodynamics (PD), and mechanistic properties of lacnotuzumab. Nonclinical investigations of the mechanism of action of lacnotuzumab were also performed to explain the observed adverse events (AEs) profile associated with CSF-1 pathway inhibition. Lacnotuzumab was generally well tolerated. The majority of AEs were low grade, no unexpected or novel AEs were observed, and there were no discontinuations for AEs. Lacnotuzumab also showed dose-dependent, on-target effects on multiple downstream biomarkers. Preclinical investigations of the CK elevation and periorbital swelling observed after lacnotuzumab administration suggest that these are reversible, nonpathological events linked to inhibition of the CSF-1 pathway. These data support further evaluation of lacnotuzumab in clinical studies. • Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction., PMID:32286255 • p53 Gain-of-Function Mutation Induces Metastasis via BRD4-Dependent CSF-1 Expression., PMID:37676642 • Pexidartinib: First Approval., PMID:31602563 • Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets., PMID:30930117 • CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment., PMID:34088832 • Osteoclast Differentiation Assay., PMID:30378050 • Colony stimulating factor-1 receptor drives glomerular parietal epithelial cell activation in focal segmental glomerulosclerosis., PMID:38428734 • Elevated expression of the colony-stimulating factor 1 (CSF1) induces prostatic intraepithelial neoplasia dependent of epithelial-Gp130., PMID:34999736 • Therapeutic advances in Tenosynovial giant cell Tumor: Targeting the CSF1/CSF1R axis., PMID:40020639 • Catechism (Quiz 13)., PMID:34341297 |
| 别名 | MCS-110, 1831128-32-5 |
| 种属 | Human |
| 备注 | For research use only. Not suitable for clinical or therapeutic use. |
相关产品:
| 产品名称 | 点击数 |
|---|---|
| 炔诺酮单抗 | 6191 |
| 磺胺氯吡嗪单抗 | 6184 |
| 呋喃苯烯酸钠单抗 | 5879 |
| 呋喃它酮代谢物（2-NPAMOZ）单抗 | 5929 |
| 呋喃西林代谢物（2-NPSEM）单抗 | 5732 |
| 磺胺喹恶啉单抗 | 6060 |
| 苯丙酸诺龙单抗 | 5968 |
| 司帕沙星单抗 | 5769 |
| 妥布霉素单抗 | 5934 |
| 甲氧氯普胺单抗 | 5772 |
| 莫能菌素单抗 | 5963 |
| 多粘菌素B（粘菌素）单抗 | 6284 |
| 磺胺类单抗 | 6244 |
| 托灭酸（托芬那酸）单抗 | 5757 |
| 卡洛芬单抗 | 5734 |
| 喹乙醇代谢物MQCA单抗 | 5849 |
| 氟尼辛单抗 | 5990 |
| 磺胺二甲嘧啶（SM2）单抗 | 5656 |
| 诺龙（19-去甲睾酮）单抗 | 5751 |
| 阿苯达唑-2-氨基砜单抗 | 5677 |
